ArticleOncotarget2017

Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.

Juan Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.